SP
GSK icon

Stablepoint Partners’s GSK GSK Stock Holding History

Stablepoint Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.75M Buy
109,711
+862
+0.8% +$45.6K 0.8% 45
2026
Q1 		$6.01M Sell
108,849
-9,644
-8% -$523K 0.89% 38
2025
Q4 		$5.81M Sell
118,493
-116
-0.1% -$5.41K 0.91% 37
2025
Q3 		$5.12M Sell
118,609
-4,685
-4% -$183K 0.81% 45
2025
Q2 		$4.73M Buy
123,294
+2,498
+2% +$95.5K 0.81% 45
2025
Q1 		$4.68M Buy
120,796
+21,232
+21% +$777K 0.85% 43
2024
Q4 		$3.37M Sell
99,564
-4,840
-5% -$174K 0.62% 57
2024
Q3 		$4.27M Buy
104,404
+135
+0.1% +$5.52K 0.78% 50
2024
Q2 		$4.17M Buy
104,269
+4
+0% +$168 0.81% 48
2024
Q1 		$4.47M Buy
104,265
+6,375
+7% +$263K 0.91% 41
2023
Q4 		$3.63M Buy
+97,890
New +$3.51M 0.93% 44

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
KIC
Keating Investment Counselors Delray Beach, Florida $364M AUM 22.11% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
AWAG
ARS Wealth Advisors Group St. Petersburg, Florida $1.28B AUM 24.51% 1-Year Est. Return
HAI
Hennessy Advisors Inc Novato, California $3.13B AUM 77.26% 1-Year Est. Return

Stablepoint Partners's GSK Position: Q2 2026 in Review

Stablepoint Partners increased its GSK (GSK) stake by 0.79% in Q2 2026, buying an estimated $45.6K and bringing the position to 109,711 shares worth $5.75M. The position accounts for 0.8% of the portfolio, ranked #45.

Stablepoint Partners first reported a position in GSK in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.01M in Q1 2026. 161 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Stablepoint Partners held 109,711 shares of GSK worth $5.75M as of Q2 2026.
  • Stablepoint Partners bought 862 GSK shares in Q2 2026, an estimated $45.6K.
  • GSK made up 0.8% of Stablepoint Partners's portfolio in Q2 2026, its #45 holding.
  • Stablepoint Partners first reported a position in GSK in Q4 2023 and has held it in 11 quarters since.
  • Stablepoint Partners's GSK position peaked at $6.01M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Stablepoint Partners's 13F filing for Q2 2026, filed 9 Jul 2026.